Tomas Simunek
Univerzita Karlova
H-index: 36
Europe-Czech Republic
Top articles of Tomas Simunek
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage | Toxicological Sciences | Veronika Keresteš Jan Kubeš Lenka Applová Petra Kollárová Olga Lenčová-Popelová | 2024/1/30 |
Hydrophobicity‐enhanced ferritin nanoparticles for efficient encapsulation and targeted delivery of hydrophobic drugs to tumor cells | Protein Science | Alessio Incocciati Jan Kubeš Roberta Piacentini Chiara Cappelletti Sofia Botta | 2023/12 |
Suppression of Anthracycline Cardiotoxicity by Dexrazoxane Is Not Mediated by Its Metal Chelating Metabolites in Rabbits and Rat Cardiomyocytes. | Acta Facultatis Pharmaceuticae Universitatis Comenianae | Eduard Jirkovský Anna Jirkovská Hana Bavlovič-Piskáčková Veronika Skalická Zuzana Pokorná | 2022/7/2 |
Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine | Scientific Reports | Pavlína Hašková Lenka Applová Hana Jansová Pavel Homola Katherine J Franz | 2022/6/13 |
Comparison of topoisomerase 2 inhibitors dexrazoxane and XK469 for the prevention of anthracycline cardiotoxicity | Mil Med Sci Lett | Veronika Skalická J Kubes Lenka Applová Galina Karabanovich Petra Brázdová | 2022 |
Abstract P3111: Can ACE Inhibitors Provide Similar Long-lasting Cardioprotection Against Chronic Anthracycline Cardiotoxicity As An Approved Drug Dexrazoxane On A Well … | Circulation Research | Martin Sterba Zuzana Pokorna Petra Kollarova Olga Lencova Jan Kubes | 2022/8/5 |
Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up | Clinical Science | Zuzana Pokorná Petra Kollárová-Brázdová Olga Lenčová-Popelová Eduard Jirkovský Jan Kubeš | 2022/1 |
Abstract P3116: Cardioprotective Effects Of Dexrazoxane Derivatives Against Chronic Anthracycline Cardiotoxicity Depend On Topoisomerase II Beta Inhibition And Prevention Of … | Circulation Research | Petra Kollarova Olga Lencova Galina Karabanovich Jan Kubes Nela Vanova | 2022/8/5 |
Structure–activity relationship study of dexrazoxane analogues reveals ICRF-193 as the most potent bisdioxopiperazine against anthracycline toxicity to cardiomyocytes due to … | Journal of medicinal chemistry | Anna Jirkovská Galina Karabanovich Jan Kubes Veronika Skalická Iuliia Melnikova | 2021/3/22 |
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity | Scientific Reports | Hana Bavlovič Piskáčková Hana Jansová Jan Kubeš Galina Karabanovich Nela Váňová | 2021/2/24 |
Clinically translatable prevention of anthracycline cardiotoxicity by dexrazoxane is mediated by topoisomerase II beta and not metal chelation | Circulation: Heart Failure | Eduard Jirkovský Anna Jirkovská Hana Bavlovič-Piskáčková Veronika Skalická Zuzana Pokorná | 2021/11 |
Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo | Clinical Science | Petra Kollárová-Brázdová Olga Lenčová-Popelová Galina Karabanovich Júlia Kocúrová-Lengvarská Jan Kubeš | 2021/8 |
Investigation of structure-activity relationships of dexrazoxane analogs reveals topoisomerase IIβ interaction as a prerequisite for effective protection against anthracycline … | Endocrinology | Maralyn R Druce James S Minnion Benjamin CT Field Sejal R Patel Joyceline C Shillito | 2009/4/1 |
